Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine

British Journal of Cancer

Volumn 102, Issue 1, 2010, Pages 144-150

  Overman, M J ^a   Pozadzides, J ^b   Kopetz, S ^a   Wen, S ^a   Abbruzzese, J L ^a   Wolff, R A ^a   Wang, H ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Epidermal growth factor receptor; Immunohistochemistry; Mismatch repair; Small bowel adenocarcinoma; Vascular endothelial growth factor

Indexed keywords

CYTOKERATIN 20; CYTOKERATIN 7; EPIDERMAL GROWTH FACTOR RECEPTOR; MISMATCH REPAIR PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRANSCRIPTION FACTOR CDX2; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMALL INTESTINE CARCINOMA; TISSUE MICROARRAY;

ADENOCARCINOMA; ADULT; AGED; DNA MISMATCH REPAIR; DUODENAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENES, ERBB-1; GENES, ERBB-2; HOMEODOMAIN PROTEINS; HUMANS; ILEAL NEOPLASMS; IMMUNOPHENOTYPING; JEJUNAL NEOPLASMS; KAPLAN-MEIERS ESTIMATE; KERATINS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENES; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 74249088974     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605449     Document Type: Article

References (36)

1. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, Flanagan A, Teague J, Futreal PA, Stratton MR, Wooster R (2004) The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 91: 355-358
2. Blaker H, von Herbay A, Penzel R, Gross S, Otto HF (2002) Genetics of adenocarcinomas of the small intestine: frequent deletions at chromosome 18q and mutations of the SMAD4 gene. Oncogene 21: 158-164
3. Brueckl WM, Heinze E, Milsmann C, Wein A, Koebnick C, Jung A, Croner RS, Brabletz T, Gunther K, Kirchner T, Hahn EG, Hohenberger W, Becker H, Reingruber B (2004) Prognostic significance of microsatellite instability in curatively resected adenocarcinoma of the small intestine. Cancer Lett 203: 181-190
4. Chen ZM, Wang HL (2004) Alteration of cytokeratin 7 and cytokeratin 20 expression profile is uniquely associated with tumorigenesis of primary adenocarcinoma of the small intestine. Am J Surg Pathol 28: 1352-1359
5. Dahia PL (2000) PTEN, a unique tumor suppressor gene. Endocr Relat Cancer 7: 115-129
6. DeSesso JM, Jacobson CF (2001) Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. Food Chem Toxicol 39: 209-228
7. Ellis LM, Hicklin DJ (2008) Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res 14: 6371-6375
8. Goel A, Arnold CN, Niedzwiecki D, Carethers JM, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR (2004) Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res 64: 3014-3021
9. Goldstein NS, Armin M (2001) Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 92: 1331-1346
10. Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, Redston M, Gallinger S (2000) Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342: 69-77
11. Hibi K, Kondo K, Akiyama S, Ito K, Takagi H (1995) Frequent genetic instability in small intestinal carcinomas. Jpn J Cancer Res 86: 357-360
12. Howe JR, Karnell LH, Menck HR, Scott-Conner C (1999) The American College of Surgeons Commission on Cancer and the American Cancer Society. Adenocarcinoma of the small bowel: review of the National Cancer Data Base, 1985-1995. Cancer 86: 2693-2706
13. Jenkins MA, Hayashi S, O'Shea AM, Burgart LJ, Smyrk TC, Shimizu D, Waring PM, Ruszkiewicz AR, Pollett AF, Redston M, Barker MA, Baron JA, Casey GR, Dowty JG, Giles GG, Limburg P, Newcomb P, Young JP, Walsh MD, Thibodeau SN, Lindor NM, Lemarchand L, Gallinger S, Haile RW, Potter JD, Hopper JL, Jass JR (2007) Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology 133: 48-56
14. Lee MJ, Lee HS, Kim WH, Choi Y, Yang M (2003) Expression of mucins and cytokeratins in primary carcinomas of the digestive system. Mod Pathol 16: 403-410
15. Liu B, Nicolaides NC, Markowitz S, Willson JK, Parsons RE, Jen J, Papadopolous N, Peltomaki P, de la Chapelle A, Hamilton SR, Kinzler KW, Vogelstein B (1995) Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat Genet 9: 48-55
16. Loy TS, Calaluce RD, Keeney GL (1996) Cytokeratin immunostaining in differentiating primary ovarian carcinoma from metastatic colonic adenocarcinoma. Mod Pathol 9: 1040-1044
17. McGregor DK, Wu TT, Rashid A, Luthra R, Hamilton SR (2004) Reduced expression of cytokeratin 20 in colorectal carcinomas with high levels of microsatellite instability. Am J Surg Pathol 28: 712-718
18. McKay JA, Murray LJ, Curran S, Ross VG, Clark C, Murray GI, Cassidy J, McLeod HL (2002) Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer 38: 2258-2264
19. Mirabelli-Primdahl L, Gryfe R, Kim H, Millar A, Luceri C, Dale D, Holowaty E, Bapat B, Gallinger S, Redston M (1999) Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res 59: 3346-3351
20. Moskaluk CA, Zhang H, Powell SM, Cerilli LA, Hampton GM, Frierson Jr HF (2003) Cdx2 protein expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays. Mod Pathol 16: 913-919
21. O'Riordan BG, Vilor M, Herrera L. (1996) Small bowel tumors: and overview. Dig Dis 14: 245-257
22. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231
23. Planck M, Ericson K, Piotrowska Z, Halvarsson B, Rambech E, Nilbert M (2003) Microsatellite instability and expression of MLH1 and MSH2 in carcinomas of the small intestine. Cancer 97: 1551-1557 (Pubitemid 36297785)
24. Rashid A, Hamilton SR (1997) Genetic alterations in sporadic and Crohn's-associated adenocarcinomas of the small intestine. Gastroenterology 113: 127-135
25. Rullier A, Le Bail B, Fawaz R, Blanc JF, Saric J, Bioulac-Sage P (2000) Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastasis. Am J Surg Pathol 24: 870-876
26. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29-39
27. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S (2004) Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96: 261-268 (Pubitemid 38256271)
28. von Rahden BH, Brucher BL, Langner C, Siewert JR, Stein HJ, Sarbia M (2006) Expression of cyclo-oxygenase 1 and 2, prostaglandin E synthase and transforming growth factor beta1, and their relationship with vascular endothelial growth factors A and C, in primary adenocarcinoma of the small intestine. Br J Surg 93: 1424-1432
29. Wang H, Wang H, Zhang W, Fuller GN (2002) Tissue microarrays: applications in neuropathology research, diagnosis, and education. Brain Pathol 12: 95-107
30. Werling RW, Yaziji H, Bacchi CE, Gown AM (2003) CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol 27: 303-310
31. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131: 18
32. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137
33. Zhang MQ, Chen ZM, Wang HL (2006) Immunohistochemical investigation of tumorigenic pathways in small intestinal adenocarcinoma: a comparison with colorectal adenocarcinoma. Mod Pathol 19: 573-580
34. Zhang MQ, Lin F, Hui P, Chen ZM, Ritter JH, Wang HL (2007) Expression of mucins, SIMA, villin, and CDX2 in small-intestinal adenocarcinoma. Am J Clin Pathol 128: 808-816
35. Zhou XP, Loukola A, Salovaara R, Nystrom-Lahti M, Peltomaki P, de la Chapelle A, Aaltonen LA, Eng C (2002) PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol 161: 439-447
36. Zhu L, Kim K, Domenico DR, Appert HE, Howard JM (1996) Adenocarcinoma of duodenum and ampulla of Vater: clinicopathology study and expression of p53, c-neu, TGF-alpha, CEA, and EMA. J Surg Oncol 61: 100-105